Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Biogen Incorporated" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Biogen Incorporated for you to read. Along with our medical data and news we also list Biogen Incorporated Clinical Trials, which are updated daily. BioPortfolio also has a large database of Biogen Incorporated Companies for you to search.
Spinraza® (nusinersen) yet to be made available by NHS England following NICE interim rejection
New medical technology category added for the first time
Superior Controls is part of an elite group of system integrators achieving the highest level of certification in the Control System Integrator Association’s Certification program and the first to pass its seventh consecutive certification audit as required every three years. SEABROOK, N.H. (PRWEB) November 15, 2018 Superior Controls, Inc., a leading 25-year-old control system integrator of cus...
40-Years of Blood Collection and Processing Proudly Supporting the Development of Life-Changing Medicines HemaCare Corporation (OTCMKTS: HEMA), a global leader in the customization of human-derived biological products and services for biomedical research and cell therapy, today announces their involvement as a provider of
Louis Arcudi III appointed as Chief Financial Officer Michael Yeh appointed as Vice President of Medical Affairs Millendo Therapeutics, Inc., a clinical-stage biotechnology company developing novel therapies for orphan endocrine diseases, today announced the appointments of Louis Arcudi III as Chief Financial Officer and Micha...
Sigilon Therapeutics, a biopharmaceutical company creating functional cures for chronic diseases using Shielded Living Therapeutics, today announced the appointment of four new members of its senior management team as the company prepares to advance its lead therapeutic candidate into clinical trials. Deya Corzo, M.D., FACMG, joins the company as Chief Med...
Anil S. Jina, M.D., Joins Akili to Build and Lead Medical Affairs Team Leading Clinicians and Researchers Will Advise on the Expansion of Akili’s Lead Investigational Product and Pipeline of Digital Medicine Products Akili Interactive (“Akili” or “Company"), a leading prescription digital medicine company developing no...
Summary 2015 - BioDuro is reacquired from PPD. BioDuro and Formex merge to enable service offerings that span from API synthesis to formulation development and cGMP manufacture of drug product. BioDuro LLC BioDuro, a subsidiary of Pharmaceutical Product Development LLC is a discoverer and developer of small molecule and biologics. The institute offers discovery, development and manufacturing...
Recognized as one of the world’s leading independent engineering firms implementing validated automation systems for the Biotech and Life Science industries, Superior Controls will exhibit November 14-15 at the 2018 Automation Fair® presented by Rockwell Automation. SEABROOK, N.H. and PHILADELPHIA (PRWEB) November 08, 2018 Superior Controls, Inc., a leading 25-year-old control system integ...
Raises 2018 Financial Guidance Conference Call Begins at 9:00 a.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and nine months ended September 30, 2018, and provided an operating forecast and program updates. Ligand management will host a conference call today b...
Expedeon’s proprietary immunoassay technology to be incorporated into Quanterix’ Simoa Planar Immunoassay products Heidelberg, Germany and Cambridge, UK, 07 November 2018 – Expedeon AG (Frankfurt: EXN; ISIN: DE000A1RFM03; Prime Standard) today announced a supply and license agreement with United States based Life Sciences company, Quanterix Corporation. The agreement provi...
Cambridge, Mass.-based Biogen exercised its option to acquire additional shares of South Korea’s Samsung Bioepis. Samsung Bioepis focuses on developing biosimilar drugs and is a joint venture between Samsung Biologics and Biogen formed in 2012.
Mannatech, Incorporated (NASDAQ: MTEX), a global health and wellness company committed to transforming lives to make a better world, today announced financial results for its third quarter of 2018. Third Quarter Results Third quarter net
Transfers shares of Samsung Bioepis for $677 million
In October 2018, two adalimumab biosimilars have been launched in the European Union (EU). Amgen announced the European launch of its adalimumab biosimilar, Amgevita and Biogen announced the launch of its adalimumab biosimilar Imraldi.
Edison Investment Research - Pharmaceutical & healthcare - Probiodrug: We believe one of the main reasons for the devaluation of Probiodrug’s shares over the past year was the largely disappointing industry newsflow frustrating research on Abeta theory, even though Probiodrug’s technology is differentiated from all other Abeta therapies studied in late-stage trials. The recent surprise...
Third Quarter Revenues of $609.7 million, up 14.0% Versus Prior Year Period; up 15.0% on Constant Currency Basis Third Quarter GAAP Diluted EPS of $1.21, down 28.8% Over the Prior Year Period Third Quarter Adjusted Diluted EPS of $2.52, up 18.9% Versus Prior Year Period Lowered 2018 Guidance Range for GAAP Revenue Growth f...
A US federal appeals court has rejected an appeal by Danish biopharma Forward Pharma against the validity of Biogen’s patent for blockbuster multiple sclerosis (MS) drug Tecfidera. The ruling frees Biogen from having to pay future royalty payments to Forward Pharma for the drug and secures the US biotech’s exclusivity on Tecfidera until 2028. Tecfidera had sales of around $4.2 billion ...
SummaryVernalis plc Vernalis is a pharmaceutical company, which focuses at developing novel pharmaceuticals for the treatment of several diseases. The product portfolio of the company comprises frovatriptan for the acute treatment of migraine; Tuzistra XR, which targets the US prescription cough cold market; and Moxatag, a onceaday formulation of the antibiotic amoxicillin, indicated for the treat...
New York (www.aktiencheck.de) - Biogen-Aktienanalyse von Analyst Jay Olson von Oppenheimer: Laut einer Aktienanalyse äußert Analyst Jay Olson vom Investmenthaus Oppenheimer weiterhin die Erwartung ...
Biogen and Eisai Co., Ltd. announced that Biogen presented results at the Clinical Trials on Alzheimer's Disease meeting, in Barcelona, Spain, from the recent 36- and 48-month analyses of the ongoing long-term extension of the Phase 1b study of aducanumab, an investigational treatment for mild cognitive impairment due to Alzheimer's disease and mild AD.